NO20052244L - Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav - Google Patents

Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav

Info

Publication number: NO20052244L
Authority: NO; Norway
Prior art keywords: hydroxy; crystal forms; carboxamide; enantiomers; dihydro
Prior art date: 2002-10-07

Application number

NO20052244A

Other languages

English (en)

Norwegian (no)

Other versions

NO20052244D0 (no

Inventor

Gottfried Sedelmeier

Sabine Pfeffer

Fritz Blatter

Christian Mathes

Dominique Grimler

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-07

Filing date

2005-05-06

Publication date

2005-07-07

2005-05-06 Application filed by Novartis Ag filed Critical Novartis Ag

2005-05-06 Publication of NO20052244D0 publication Critical patent/NO20052244D0/no

2005-07-07 Publication of NO20052244L publication Critical patent/NO20052244L/no

Links

239000013078 crystal Substances 0.000 title abstract 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 2
BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
210000000349 chromosome Anatomy 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
229910052741 iridium Inorganic materials 0.000 abstract 1
229910052742 iron Inorganic materials 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229910052759 nickel Inorganic materials 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
229910052703 rhodium Inorganic materials 0.000 abstract 1
229910052707 ruthenium Inorganic materials 0.000 abstract 1
238000009901 transfer hydrogenation reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20052244A 2002-10-07 2005-05-06 Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav NO20052244L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0223224.7A GB0223224D0 (en)	2002-10-07	2002-10-07	Organic compounds
PCT/EP2003/011034 WO2004031155A1 (en)	2002-10-07	2003-10-06	ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF

Publications (2)

Publication Number	Publication Date
NO20052244D0 NO20052244D0 (no)	2005-05-06
NO20052244L true NO20052244L (no)	2005-07-07

Family

ID=9945425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052244A NO20052244L (no)	2002-10-07	2005-05-06	Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav

Country Status (20)

Country	Link
US (1)	US20060142566A1 (es)
EP (1)	EP1551808A1 (es)
JP (1)	JP2006504710A (es)
KR (1)	KR20050071549A (es)
CN (2)	CN101062932A (es)
AR (1)	AR041544A1 (es)
AU (1)	AU2003276055B2 (es)
BR (1)	BR0315113A (es)
CA (1)	CA2501237A1 (es)
EC (1)	ECSP055738A (es)
GB (1)	GB0223224D0 (es)
HK (1)	HK1079790A1 (es)
MX (1)	MXPA05003737A (es)
NO (1)	NO20052244L (es)
PE (1)	PE20040686A1 (es)
PL (1)	PL376379A1 (es)
RU (1)	RU2005114350A (es)
TW (1)	TW200413324A (es)
WO (1)	WO2004031155A1 (es)
ZA (1)	ZA200502561B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0303615D0 (en) *	2003-02-17	2003-03-19	Novartis Ag	Use of organic compounds
GB0425320D0 (en)	2004-11-17	2004-12-22	Johnson Matthey Plc	Diamines
US20060252745A1 (en)	2005-05-06	2006-11-09	Almeida Jose L D	Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0515690D0 (en)	2005-07-29	2005-09-07	Portela & Ca Sa	Asymmetric catalytic reduction
GB2437078A (en) *	2006-04-11	2007-10-17	Portela & Ca Sa	10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
JP5172124B2 (ja) *	2006-09-29	2013-03-27	関東化学株式会社	２位に置換基を有する光学活性キヌクリジノール類の製造方法
GB0700773D0 (en)	2007-01-15	2007-02-21	Portela & Ca Sa	Drug therapies
WO2011045648A2 (en) *	2009-10-12	2011-04-21	Matrix Laboratories Limited	Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
EP2383261B1 (en)	2010-04-23	2013-09-04	Euticals GmbH	Process for the asymmetric hydrogenation of ketones
CN102250005B (zh) *	2010-05-19	2015-04-08	浙江九洲药物科技有限公司	艾利西平的制备方法
ES2687678T3 (es) *	2011-03-08	2018-10-26	Jubilant Life Sciences Limited	Procedimiento para la preparación de (S)-(+)-10,11-dihidro-10-hidroxi-5H-dibenzo[b,f]azepina-5-carboxamida y ésteres de la misma mediante reducción enantioselectiva de 10,11-dihidro-10-oxo-5H-dibenzo[b,f]azepina-5-carboxamida
US9303038B2 (en)	2011-09-06	2016-04-05	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy and neurological diseases
SG11201407300VA (en) *	2012-05-07	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of depression
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9266823B2 (en)	2012-05-08	2016-02-23	Cellix Bio Private Limited	Compositions and methods for the treatment of parkinson's disease
US9309233B2 (en)	2012-05-08	2016-04-12	Cellix Bio Private Limited	Compositions and methods for the treatment of blood clotting disorders
US9403826B2 (en)	2012-05-08	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en)	2012-05-08	2016-12-20	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological degenerative disorders
WO2013168001A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
US9573927B2 (en)	2012-05-10	2017-02-21	Cellix Bio Private Limited	Compositions and methods for the treatment of severe pain
US9242939B2 (en)	2012-05-10	2016-01-26	Cellix Bio Private Limited	Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en)	2012-05-10	2016-03-01	Cellix Bio Private Limited	Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurologic diseases
US9499526B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of neurologic diseases
US9233161B2 (en)	2012-05-10	2016-01-12	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological conditions
US9346742B2 (en)	2012-05-10	2016-05-24	Cellix Bio Private Limited	Compositions and methods for the treatment of fibromyalgia pain
US9339484B2 (en)	2012-05-10	2016-05-17	Cellix Bio Private Limited	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168015A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of asthma and allergy
US9403857B2 (en)	2012-05-10	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
WO2013167997A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013168014A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of familial amyloid polyneuropathy
US9434729B2 (en)	2012-05-23	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
SG11201407326XA (en)	2012-05-23	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for treatment of mucositis
NZ701832A (en)	2012-05-23	2016-08-26	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammatory bowel disease
WO2013175347A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of local pain
JP2015518854A (ja)	2012-05-23	2015-07-06	セリックスビオプライヴェートリミテッド	多発性硬化症の治療のための組成物および方法
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en)	2012-08-03	2015-11-17	Cellix Bio Private Limited	N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en)	2012-09-08	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of inflammation and lipid disorders
EP2900640A1 (en)	2012-09-26	2015-08-05	Ranbaxy Laboratories Limited	Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en)	2013-06-04	2015-12-24	Cellixbio Private Limited	Compositions and methods for the treatment of diabetes and pre-diabetes
JP6461939B2 (ja) *	2013-07-01	2019-01-30	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ケトン類を不斉還元するための新規なルテニウム触媒及びその使用
CN103483257A (zh) *	2013-09-06	2014-01-01	江苏同禾药业有限公司	一种亚氨基芪的合成方法
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
SG11201706952VA (en)	2014-09-26	2017-10-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en)	2014-09-29	2020-03-18	Cellix Bio Private Limited	Compounds and compositions for the treatment of multiple sclerosis
AU2014414316B2 (en)	2014-10-27	2020-04-09	Cellix Bio Private Limited	Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
WO2016088132A1 (en)	2014-12-01	2016-06-09	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja)	2015-01-06	2020-04-22	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	炎症及び疼痛の治療のための組成物及び方法
EP3064490A1 (en)	2015-03-06	2016-09-07	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
CN107033079B (zh) *	2016-10-17	2020-07-28	扬子江药业集团北京海燕药业有限公司	醋酸艾司利卡西平的制备方法
CN112679433B (zh) *	2019-10-18	2024-05-24	浙江九洲药业股份有限公司	一种艾利西平的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT101732B (pt) *	1995-06-30	1997-12-31	Portela & Ca Sa	Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
CA2374553A1 (fr) *	1999-06-15	2000-12-21	Rhodia Chimie	Sulfonylamides et carboxamides et leur application en catalyse asymetrique
CA2437402A1 (en) *	2001-02-12	2002-08-22	Teva Pharmaceutical Industries, Ltd.	New crystal forms of oxcarbazepine and processes for their preparation

2002
- 2002-10-07 GB GBGB0223224.7A patent/GB0223224D0/en not_active Ceased
2003
- 2003-10-06 BR BR0315113-1A patent/BR0315113A/pt not_active IP Right Cessation
- 2003-10-06 CN CNA2007101126346A patent/CN101062932A/zh active Pending
- 2003-10-06 CA CA002501237A patent/CA2501237A1/en not_active Abandoned
- 2003-10-06 MX MXPA05003737A patent/MXPA05003737A/es not_active Application Discontinuation
- 2003-10-06 HK HK05112208.8A patent/HK1079790A1/zh unknown
- 2003-10-06 RU RU2005114350/04A patent/RU2005114350A/ru not_active Application Discontinuation
- 2003-10-06 AU AU2003276055A patent/AU2003276055B2/en not_active Expired - Fee Related
- 2003-10-06 JP JP2004540788A patent/JP2006504710A/ja active Pending
- 2003-10-06 CN CNA2003801013117A patent/CN1703404A/zh active Pending
- 2003-10-06 EP EP03798930A patent/EP1551808A1/en not_active Withdrawn
- 2003-10-06 KR KR1020057005920A patent/KR20050071549A/ko not_active Withdrawn
- 2003-10-06 PL PL03376379A patent/PL376379A1/xx unknown
- 2003-10-06 US US10/530,617 patent/US20060142566A1/en not_active Abandoned
- 2003-10-06 WO PCT/EP2003/011034 patent/WO2004031155A1/en not_active Ceased
- 2003-10-07 TW TW092127799A patent/TW200413324A/zh unknown
- 2003-10-07 AR ARP030103648A patent/AR041544A1/es not_active Application Discontinuation
- 2003-10-07 PE PE2003001022A patent/PE20040686A1/es not_active Application Discontinuation
2005
- 2005-03-30 ZA ZA200502561A patent/ZA200502561B/en unknown
- 2005-04-06 EC EC2005005738A patent/ECSP055738A/es unknown
- 2005-05-06 NO NO20052244A patent/NO20052244L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20060142566A1 (en)	2006-06-29
CN101062932A (zh)	2007-10-31
PE20040686A1 (es)	2004-10-29
GB0223224D0 (en)	2002-11-13
HK1079790A1 (zh)	2006-04-13
ECSP055738A (es)	2005-07-06
EP1551808A1 (en)	2005-07-13
KR20050071549A (ko)	2005-07-07
NO20052244D0 (no)	2005-05-06
RU2005114350A (ru)	2006-01-20
AU2003276055B2 (en)	2008-01-03
MXPA05003737A (es)	2005-06-17
BR0315113A (pt)	2005-08-23
AR041544A1 (es)	2005-05-18
JP2006504710A (ja)	2006-02-09
PL376379A1 (en)	2005-12-27
CN1703404A (zh)	2005-11-30
WO2004031155A1 (en)	2004-04-15
AU2003276055A1 (en)	2004-04-23
ZA200502561B (en)	2006-02-22
TW200413324A (en)	2004-08-01
CA2501237A1 (en)	2004-04-15

Legal Events

Date	Code	Title	Description
2009-05-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
HK1079790A1 (zh)	2006-04-13	10，11-二氢-10-羟基-5h-二苯并b，f氮杂卓-5-羧酰胺的对映体及其新晶形两者制备的对映选择性方法
EP2598482B1 (en)	2018-04-04	Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
TW200901993A (en)	2009-01-16	Triazolopyridine carboxamide and triazolopyrimidine carboxamide derivatives, their preparation and their application in therapeutics
MX2011002705A (es)	2011-09-09	Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
JP2017508798A (ja)	2017-03-30	ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
TW202515876A (zh)	2025-04-16	Tyk2抑制劑及其用途
EP2598480A1 (en)	2013-06-05	Cyclopropylamine derivatives useful as lsd1 inhibitors
RU2683022C1 (ru)	2019-03-26	Производные гетероциклические алкильные соединения в качестве селективных ингибиторов гистондеацетилазы и содержащие их фармацевтические композиции
MX2012010658A (es)	2012-12-05	Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
Taha et al.	2015	Synthesis of potent urease inhibitors based on disulfide scaffold and their molecular docking studies
EP4305021A1 (en)	2024-01-17	Usp30 inhibitors and uses thereof
JP2025510844A (ja)	2025-04-15	Ｔｙｋ２阻害剤の合成及びその中間体
FR2780649A1 (fr)	2000-01-07	Derives de la piperazine pour l'inhibition de la replication du virus de l'immunodeficience humaine
NO20064752L (no)	2006-11-20	N-piperidinderivater som CCR3-modulatorer
TW200602297A (en)	2006-01-16	Sulfonamide compounds for the treatment of neurodegenerative disorders
TWI422367B (zh)	2014-01-11	An onion quinone derivative for inhibiting cancer and a method for producing the same
CN111065619B (zh)	2022-08-12	(E)-α,β-不饱和酰胺化合物及其制备方法和用途
CN111303046A (zh)	2020-06-19	含手性羟亚甲基结构的联苯二芳基嘧啶类衍生物及其制备方法和用途
Hoang et al.	2023	Discovery of 1H-indazole-6-amine Derivatives as Anticancer Agents: Simple But Effective
EP3720855A1 (en)	2020-10-14	Imidazopyridine derivatives and the use thereof as medicament
DE60107505D1 (de)	2005-01-05	Wirksame Derivate der Valproinsäure zur Behandlung von neurologischen und psychotischen Störungen, und ein Verfahren zu ihrer Herstellung
CN109890798A (zh)	2019-06-14	用于治疗cns病症的羟基去甲氯胺酮衍生物
RU2830281C1 (ru)	2024-11-18	Вещества, обеспечивающие деградацию белков, и их применения
Ramudua et al.	2019	Synthesis, spectral characterization and bioactivity evaluation of sulfonamide derivatives of p-nitrobenzene sulfonylchloride
WO2015129603A1 (ja)	2015-09-03	活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤の高純度結晶